Maria M M Santos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3467974/publications.pdf

Version: 2024-02-01

61 papers	1,902 citations	236925 25 h-index	265206 42 g-index
73 all docs	73 docs citations	73 times ranked	2323 citing authors

#	Article	IF	Citations
1	Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis. Pharmacological Research, 2022, 175, 106026.	7.1	3
2	Recent Progress in the Development of Indole-Based Compounds Active against Malaria, Trypanosomiasis and Leishmaniasis. Molecules, 2022, 27, 319.	3.8	17
3	Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity. European Journal of Medicinal Chemistry, 2022, 236, 114324.	5.5	9
4	Potency and Selectivity Optimization of Tryptophanolâ€Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer. ChemMedChem, 2021, 16, 250-258.	3.2	6
5	Exploiting the antiproliferative potential of spiropyrazoline oxindoles in a human ovarian cancer cell line. Bioorganic and Medicinal Chemistry, 2021, 30, 115880.	3.0	12
6	Tryptophanol-Derived Oxazolopyrrolidone Lactams as Potential Anticancer Agents against Gastric Adenocarcinoma. Pharmaceuticals, 2021, 14, 208.	3.8	3
7	Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance. Cancers, 2021, 13, 1648.	3.7	11
8	Pharmacological Treatment of Malaria. Topics in Medicinal Chemistry, 2021, , 219-240.	0.8	1
9	SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129440.	2.4	13
10	PPIs as therapeutic targets for anticancer drug discovery: the case study of MDM2 and BET bromodomain inhibitors. , 2020, , 267-288.		1
11	SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner. International Journal of Molecular Sciences, 2020, 21, 596.	4.1	17
12	Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders. European Journal of Medicinal Chemistry, 2020, 194, 112242.	5.5	2
13	Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment. Current Medicinal Chemistry, 2020, 26, 7323-7336.	2.4	13
14	SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. Cancers, 2019, 11, 1151.	3.7	21
15	A Novel Small Molecule p53 Stabilizer for Brain Cell Differentiation. Frontiers in Chemistry, 2019, 7, 15.	3.6	10
16	Improving anticancer activity towards colon cancer cells with a new p53â€activating agent. British Journal of Pharmacology, 2018, 175, 3947-3962.	5.4	21
17	A More Sustainable Process for Preparation of the Muscarinic Acetylcholine Antagonist Umeclidinium Bromide. ChemMedChem, 2018, 13, 2053-2056.	3.2	0
18	An Update on MDMX and Dual MDM2/X Inhibitors. Current Topics in Medicinal Chemistry, 2018, 18, 647-660.	2.1	39

#	Article	IF	Citations
19	Optimization of Bicyclic Lactam Derivatives as NMDA Receptor Antagonists. ChemMedChem, 2017, 12, 537-545.	3.2	5
20	DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Molecular Oncology, 2017, 11, 612-627.	4.6	33
21	Spirotriazoline oxindoles: A novel chemical scaffold with inÂvitro anticancer properties. European Journal of Medicinal Chemistry, 2017, 140, 494-509.	5.5	27
22	InÂvitro targeting of colon cancer cells using spiropyrazoline oxindoles. European Journal of Medicinal Chemistry, 2017, 139, 168-179.	5.5	29
23	Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists. Molecules, 2016, 21, 1027.	3.8	4
24	Chemical Variations on the p53 Reactivation Theme. Pharmaceuticals, 2016, 9, 25.	3.8	28
25	Novel squaramides with in vitro liver stage antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2016, 24, 1786-1792.	3.0	17
26	Spirooxadiazoline oxindoles with promising in vitro antitumor activities. MedChemComm, 2016, 7, 420-425.	3.4	24
27	Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. Oncotarget, 2016, 7, 4326-4343.	1.8	37
28	Enantiopure Indolizinoindolones with in vitro Activity against Bloodâ€•and Liverâ€Stage Malaria Parasites. ChemMedChem, 2015, 10, 2080-2089.	3.2	30
29	1.2 Designing Covalent Inhibitors: A Medicinal Chemistry Challenge. , 2015, , 44-60.		2
30	A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins. Pharmacological Research, 2015, 95-96, 42-52.	7.1	37
31	Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53â€“MDM2 interaction. European Journal of Pharmaceutical Sciences, 2015, 66, 138-147.	4.0	41
32	Indolo[2,3-a]quinolizidines and Derivatives: Bioactivity and Asymmetric Synthesis. Current Pharmaceutical Design, 2015, 21, 5518-5546.	1.9	12
33	Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents. Bioorganic and Medicinal Chemistry, 2014, 22, 577-584.	3.0	56
34	Recent advances in the synthesis of biologically active spirooxindoles. Tetrahedron, 2014, 70, 9735-9757.	1.9	334
35	Tryptophanol-derived oxazolopiperidone lactams: Identification of a hit compound as NMDA receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3333-3336.	2.2	9
36	Synthesis of novel spiropyrazoline oxindoles and evaluation of cytotoxicity in cancer cell lines. European Journal of Medicinal Chemistry, 2014, 79, 266-272.	5.5	84

#	Article	IF	Citations
37	Synthesis of phenylalaninol-derived oxazolopyrrolidone lactams and evaluation as NMDA receptor antagonists. Monatshefte FÃ¼r Chemie, 2013, 144, 473-477.	1.8	13
38	Squaric acid/4-aminoquinoline conjugates: Novel potent antiplasmodial agents. European Journal of Medicinal Chemistry, 2013, 69, 365-372.	5.5	21
39	Synthetic Condensed 1,4-naphthoquinone Derivative Shifts Neural Stem Cell Differentiation by Regulating Redox State. Molecular Neurobiology, 2013, 47, 313-324.	4.0	21
40	Enantioselective formal synthesis of ent-rhynchophylline and ent-isorhynchophylline. Chemical Communications, 2013, 49, 1954.	4.1	37
41	Enhancing Macrocyclic Diterpenes as Multidrug-Resistance Reversers: Structureâ€“Activity Studies on Jolkinol D Derivatives. Journal of Medicinal Chemistry, 2013, 56, 748-760.	6.4	61
42	Squaric acid: a valuable scaffold for developing antimalarials?. MedChemComm, 2012, 3, 489.	3.4	34
43	Efficient synthesis of spiroisoxazoline oxindoles. Tetrahedron Letters, 2012, 53, 281-284.	1.4	31
44	Aza vinyl sulfones: Synthesis and evaluation as antiplasmodial agents. Bioorganic and Medicinal Chemistry, 2011, 19, 7635-7642.	3.0	24
45	Stereocontrolled Generation of Benzo[aâ€•and Indolo[2,3â€a]quinolizidines from (S)â€Tryptophanol and (S)â€(3,4â€Dimethoxyphenyl)alaninolâ€Derived Lactams. European Journal of Organic Chemistry, 2011, 2011, 3858-3863.	2.4	14
46	Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials. European Journal of Medicinal Chemistry, 2011, 46, 927-933.	5.5	33
47	Aspartic vinyl sulfones: Inhibitors of a caspase-3-dependent pathway. European Journal of Medicinal Chemistry, 2011, 46, 2141-2146.	5.5	25
48	Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. AÂstructureâ€“activity study. European Journal of Medicinal Chemistry, 2010, 45, 3858-3863.	5.5	34
49	Reaction of naphthoquinones with substituted nitromethanes. Facile synthesis and antifungal activity of naphtho[2,3-d]isoxazole-4,9-diones. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 193-195.	2.2	94
50	Cell Death Targets and Potential Modulators in Alzheimers Disease. Current Pharmaceutical Design, 2010, 16, 2851-2864.	1.9	36
51	Naphtho[2,3-d]isoxazole-4,9-dione-3-carboxylates: Potent, non-cytotoxic, antiapoptotic agents. Chemico-Biological Interactions, 2009, 180, 175-182.	4.0	10
52	Enantioselective Formal Synthesis of (+)-Dihydrocorynantheine and (âˆ')-Dihydrocorynantheol. Journal of Organic Chemistry, 2009, 74, 1205-1211.	3.2	43
53	Michael Acceptors as Cysteine Protease Inhibitors. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1040-1050.	2.4	130
54	Straightforward Methodology for the Enantioselective Synthesis of Benzo[a]- and Indolo[2,3-a]quinolizidines. Journal of Organic Chemistry, 2007, 72, 5193-5201.	3.2	58

#	Article	IF	Citations
55	Enantioselective Spirocyclizations from Tryptophanol-Derived Oxazolopiperidone Lactams. Organic Letters, 2007, 9, 2907-2910.	4.6	35
56	Complementary routes for the stereoselective synthesis of functionalized benzoquinolizidine targets. Tetrahedron Letters, 2006, 47, 5713-5716.	1.4	24
57	Synthesis of 3-acetonyl- and 3-(2-oxoethyl)glutarates. Tetrahedron, 2005, 61, 7693-7702.	1.9	13
58	Biogenetically Inspired Enantioselective Approach to Indolo[2,3-a]- and Benzo[a]quinolizidine Alkaloids from a Synthetic Equivalent of Secologanin. Organic Letters, 2005, 7, 2817-2820.	4.6	39
59	A new approach to N-protected staurosporinones. Tetrahedron Letters, 2004, 45, 2347-2349.	1.4	17
60	A short synthesis of staurosporinone (K-252c). Tetrahedron Letters, 2003, 44, 2577-2578.	1.4	25
61	A novel synthesis of arcyriaflavin-A via an intramolecular sulfur extrusion reaction. Tetrahedron Letters, 2000, 41, 9835-9838.	1.4	21